ReviewUrologic oncology2017
Advances in medical imaging for the diagnosis and management of common genitourinary cancers.
Review in Urologic oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Rs-10889677 variant in interleukin-23 receptor may contribute to creating an inflammatory milieu more susceptible to bladder tumourigenesis: report and meta-analysis.Immunogenetics · 2021Pooled it
- Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma.Journal of Zhejiang University. Science. B · 2026Article
- Harnessing Artificial Intelligence for the Detection and Management of Colorectal Cancer Treatment.Cancer prevention research (Philadelphia, Pa.) · 2024Review
- Neighborhood social vulnerability and disparities in time to kidney cancer surgical treatment and survival in Arizona.Cancer medicine · 2024Article
- Role of ultra-high b-value DWI in the imaging of hereditary leiomyomatosis and renal cell carcinoma (HLRCC).Abdominal radiology (New York) · 2023Article
- Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma.Biomedicines · 2022Review
- Role of 18F-FDG PET/CT for detection of recurrence and metastases in renal cell carcinoma-are we underusing PET/CT?Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- [Modern tomography imaging techniques in urological diseases].Der Urologe. Ausg. A · 2022Review
- Association between prostatic 18F-FDG uptake and lower urinary tract symptoms assessed by International Prostate Symptom Score.Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
- Clinical value ofUrologic oncology · 2021Article
- Utility ofAJR. American journal of roentgenology · 2021Article
- Updated Trends in Cancer in Japan: Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence.Journal of epidemiology · 2021Article
- Article
- Systematic imaging in medicine: a comprehensive review.European journal of nuclear medicine and molecular imaging · 2021Review
- The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs.Nature reviews. Urology · 2020Review
- A review of current advancements and limitations of artificial intelligence in genitourinary cancers.American journal of clinical and experimental urology · 2020Review
- [Influence of immunomodulators on urological imaging].Der Urologe. Ausg. A · 2019Review
- The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages.International journal of epidemiology · 2019Article
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Medical imaging of the 3 most common genitourinary (GU) cancers-prostate adenocarcinoma, renal cell carcinoma, and urothelial carcinoma of the bladder-has evolved significantly during the last decades. The most commonly used imaging modalities for the diagnosis, staging, and follow-up of GU cancers are computed tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET). Multiplanar multidetector computed tomography and multiparametric MRI with diffusion-weighted imaging are the main imaging modalities for renal cell carcinoma and urothelial carcinoma, and although multiparametric MRI is rapidly becoming the main imaging tool in the evaluation of prostate adenocarcinoma, biopsy is still required for diagnosis. Functional and molecular imaging using 18-fluorodeoxyglucose-PET and sodium fluoride-PET are essential for the diagnosis, and especially follow-up, of metastatic GU tumors. This review provides an overview of the latest advances in the imaging of these 3 major GU cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.